Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 3/20 | 0.47 |
| ▸ | PKM | P14618 | 2/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.47 |
| ▸ | ALPI | P09923 | 1/20 | 0.47 |
| ▸ | XIAP | P98170 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.44 |
| ▸ | USP2 | O75604 | 3/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | RECQL | P46063 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | RGS12 | O14924 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
| ▸ | CASP1 | P29466 | 1/20 | 0.43 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.43 |
| ▸ | THPO | P40225 | 1/20 | 0.43 |
| ▸ | CASP7 | P55210 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15390388 | 1.00 | SLC7A5 (0.47) | SLC7A5PKMPTGS1ALPIXIAP | |
| SCHEMBL4242870 | 1.00 | SLC7A5 (0.47) | SLC7A5PKMPTGS1ALPIXIAP | |
| SCHEMBL9172559 | 0.87 | SLC7A5 (0.55) | SLC7A5PKMPTGS1ALPIXIAP | |
| SCHEMBL16065008 | 0.86 | CES2 (0.42) | SLC7A5PKMPTGS1ALPIXIAP | |
| SCHEMBL16131652 | 0.84 | L3MBTL1 (0.44) | SLC7A5PKMPTGS1ALPIXIAP | |
| SCHEMBL14340878 | 0.83 | CYP2C19 (0.48) | KDM4ETDP1ALDH1A1HPGDKMT2A | |
| SCHEMBL12219566 | 0.81 | L3MBTL1 (0.39) | KDM4ETDP1CYP3A4CYP2C9ALDH1A1 | |
| SCHEMBL12194029 | 0.80 | L3MBTL1 (0.38) | KDM4ETDP1ALDH1A1MAPTHPGD | |
| SCHEMBL14780592 | 0.80 | HSD17B10 (0.49) | SLC7A5PKMPTGS1ALPIXIAP | |
| Hydrochloric Acid SCHEMBL3749054 | 0.79 | ALDH1A1 (0.40) | HSD17B10KDM4EMEN1ALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12371454-B2 | Cyclic peptide compound having Kras inhibitory action | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-07-29 | — | — | US | disclosed |
| US-20240400617-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-12-05 | — | — | US | disclosed |
| US-20240148821-A1 | PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-05-09 | — | — | US | disclosed |
| EP-4316503-A1 | PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-02-07 | — | — | EP | disclosed |
| CN-117279655-A | Pharmaceutical use of cyclic peptide compounds | 中外制药株式会社 | 2023-12-22 | — | — | CN | disclosed |
| US-11807635-B2 | Nitrile derivative that acts as inhibitor of dipeptidyl peptidase 1 and use thereof | HAISCO PHARMACEUTICALS PTE. LTD. (SG) | 2023-11-07 | — | — | US | disclosed |
| US-11807635-B2 | Nitrile derivative that acts as inhibitor of dipeptidyl peptidase 1 and use thereof | HAISCO PHARMACEUTICALS PTE. LTD. (SG) | 2023-11-07 | — | — | US | disclosed |
| WO-2023134656-A1 | PEPTIDYL NITRILE COMPOUND AND USE THEREOF | 上海壹典医药科技开发有限公司 | 2023-07-20 | — | — | WO | disclosed |
| US-20230151060-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-05-18 | — | — | US | disclosed |
| US-20230151060-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-05-18 | — | — | US | disclosed |
| US-20030105080-A1 | Thienylalanine derivatives as inhibitors of cell adhesion | AVENTIS PHARMA S.A. DEUTSCHLAND GMBH (DE) | 2003-06-05 | — | — | US | disclosed |
| EP-1240161-A1 | THIENYLALANINE DERIVATIVES AS INHIBITORS OF CELL ADHESION | Aventis Pharma Deutschland GmbH (DE) | 2002-09-18 | — | — | EP | disclosed |
| WO-2001044237-A1 | THIENYLALANINE DERIVATIVES AS INHIBITORS OF CELL ADHESION | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2001-06-21 | — | — | WO | disclosed |
| EP-1108721-A1 | Thienylalanine derivatives as inhibitors of cell adhesion | Aventis Pharma Deutschland GmbH (DE) | 2001-06-20 | — | — | EP | disclosed |
| EP-0581250-B1 | Process for biotechnical preparation of L-thienylalanines in enantiomere pure form from 2-hydroxy-3-thienyl-acrylic acids and their use | HOECHST AG (DE) | 1999-03-03 | — | — | EP | disclosed |
| US-5780640-A | Process for the biotechnological preparation of L-thienylalanines in enantiomerically pure form from 2-hydroxy-3-thienylacrylic acids and their use | HOECHST AKTIENGESELLSCHAFT (DE) | 1998-07-14 | — | — | US | disclosed |
| US-5688672-A | Process for the biotechnological preparation of L-thienylalanines in enantiomerically pure form from 2-hydroxy-3-thienylacrylic acids | HOECHST AKTIENGESELLSCHAFT (DE) | 1997-11-18 | — | — | US | disclosed |
| US-5480786-A | Process for the biotechnological preparation of l-thienylalanines in enantiomerically pure form from 2-hydroxy-3-thienylacrylic acids, and their use | HOECHST AKTIENGESELLSCHAFT (DE) | 1996-01-02 | — | — | US | disclosed |
| WO-1994008577-A1 | FIBRINOGEN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 1994-04-28 | — | — | WO | disclosed |
| EP-0581250-A2 | Process for biotechnical preparation of L-thienylalanines in enantiomere pure form from 2-hydroxy-3-thienyl-acrylic acids and their use | HOECHST AKTIENGESELLSCHAFT (DE) | 1994-02-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11807635-B2 | Nitrile derivative that acts as inhibitor of dipeptidyl peptidase 1 and use thereof | DPP4, DPP3, DPP9 | SLC7A5 1676/4885PKM 4368/4885PTGS1 937/4885 |
| US-20030105080-A1 | Thienylalanine derivatives as inhibitors of cell adhesion | VCAM1, TEK, ADGRF1 | SLC7A5 659/4885PKM 1349/4885PTGS1 370/4885 |
| US-20230151060-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | KRAS, NRAS, HRAS | SLC7A5 2107/4885PKM 4478/4885PTGS1 3209/4885 |
| US-20240400617-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | KRAS, NRAS, HRAS | SLC7A5 2107/4885PKM 4478/4885PTGS1 3209/4885 |
| US-20240148821-A1 | PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND | VIP, IAPP, KRAS | SLC7A5 1197/4885PKM 3616/4885PTGS1 3655/4885 |
| US-12371454-B2 | Cyclic peptide compound having Kras inhibitory action | KRAS, NRAS, HRAS | SLC7A5 2107/4885PKM 4478/4885PTGS1 3209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.